ALX Oncology, a Bay Area biotech firm currently running clinical trials for its anticancer therapy, announced Wednesday that it’s laying off about 30% of its staff. ALX shared the news in a press ...
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker. The drug, called evorpacept, is in a pair of phase 2 trials for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback